Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists

The inflammatory Bowel diseases (IBDs) are a chronic, relapsing inflammatory diseases of the gastrointestinal tract with heterogeneous behavior and prognosis. The introduction of biological therapies including anti-TNF, anti-IL-12/23, and anti-integrins, has revolutionized the treatment of IBD, but...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Tamara Pérez-Jeldres, Christopher J. Tyler, Joshua D. Boyer, Thangaraj Karuppuchamy, Andrés Yarur, Daniel A. Giles, Shaila Yeasmin, Luke Lundborg, William J. Sandborn, Derek R. Patel, Jesús Rivera-Nieves
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Frontiers Media S.A. 2019-03-01
Saila:Frontiers in Pharmacology
Gaiak:
IBD
small molecules
JAK inhibitors
S1P agonists
MOA
Sarrera elektronikoa:https://www.frontiersin.org/article/10.3389/fphar.2019.00212/full
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak